April 2026
Serotonin
What April 2026's 8 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in April 2026 focused on the pharmacology and therapeutic potential of serotonergic psychedelics, with studies showing that 2-halogenated tryptamines reduce 5-HT2A activity and psychedelic potential while preserving other receptor engagement, and that psilocybin induces a conserved gene expression signature across brain regions. Findings are consistent in supporting the relevance of 5-HT2A signaling for psychedelic effects and potential therapeutic applications, but evidence is largely preclinical or theoretical, with limited clinical data and small sample sizes.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders. 2026 | theoretical | Supports | Argues that novel indoline derivatives acting as 5-HT2A agonists may serve as serotonergic psychedelic agents for treating psychosis, mental illness, and CNS disorders. | |
| Serotonergic Polypharmacology of 2-Halogenated Tryptamines. 2026 | experimental study | Supports | 2-Halogenation of DMT and psilacetin reduced 5-HT2A and 5-HT2B activity while preserving 5-HT6 agonism, and 2-Br-psilacetin showed reduced psychedelic potential and improved stress-related behavior in mice. | |
| Pathway-selective signaling of serotonergic psychedelics at 5-HT receptors: Implications for psychoactivity, safety, and therapeutic potential 2026 | in vitro pharmacological study | Supports | IP1 formation via PLC activation was the most robust measure of 5-HT2 receptor activation and correlated strongly with known psychoactive doses of serotonergic psychedelics. | |
| Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat. 2026 | experimental study | 24 | Supports | Psilocybin upregulated Nfkbia and Sgk1 across all studied brain regions and did not alter expression of genes related to serotonergic or other neurotransmitter signaling. |
| Dorsal Raphe Revisited: A Systems Neuroscience Lens on Psychedelic Drug Action 2026 | review | Unclear | Reviews the historical shift from early hypotheses that raphe serotonergic neurons drive hallucinogenic effects to current understanding of psychedelic action through neurophysiology. | |
| Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes. 2026 | theoretical or philosophical paper | Supports | Argues that classic hallucinogens may restore mitochondrial integrity in Alzheimer's disease via 5-HT2A and sigma-1 receptor pathways, but evidence remains preclinical and hypothesis-generating. | |
| Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats. 2026 | preclinical experimental study | 8 | Mixed | Psilocin selectively decreased phase-locking index at 40 Hz stimulation in the right temporal cortex, with no significant changes in frontal or left temporal regions or at 80 Hz stimulation. |
| Features of connectivity of default mode network depending on polymorphism of serotonin transporter gene (5-HTTLPR). 2026 | observational cohort | Supports | Polymorphism of the serotonin transporter gene (5-HTTLPR) is associated with differences in default mode network connectivity. |
Argues that novel indoline derivatives acting as 5-HT2A agonists may serve as serotonergic psychedelic agents for treating psychosis, mental illness, and CNS disorders.
theoretical
2-Halogenation of DMT and psilacetin reduced 5-HT2A and 5-HT2B activity while preserving 5-HT6 agonism, and 2-Br-psilacetin showed reduced psychedelic potential and improved stress-related behavior in mice.
experimental study
IP1 formation via PLC activation was the most robust measure of 5-HT2 receptor activation and correlated strongly with known psychoactive doses of serotonergic psychedelics.
in vitro pharmacological study
Psilocybin upregulated Nfkbia and Sgk1 across all studied brain regions and did not alter expression of genes related to serotonergic or other neurotransmitter signaling.
experimental study Sample size: 24
Reviews the historical shift from early hypotheses that raphe serotonergic neurons drive hallucinogenic effects to current understanding of psychedelic action through neurophysiology.
review
Argues that classic hallucinogens may restore mitochondrial integrity in Alzheimer's disease via 5-HT2A and sigma-1 receptor pathways, but evidence remains preclinical and hypothesis-generating.
theoretical or philosophical paper
Psilocin selectively decreased phase-locking index at 40 Hz stimulation in the right temporal cortex, with no significant changes in frontal or left temporal regions or at 80 Hz stimulation.
preclinical experimental study Sample size: 8
Polymorphism of the serotonin transporter gene (5-HTTLPR) is associated with differences in default mode network connectivity.
observational cohort
Points of agreement
- 5-HT2A receptor activation is central to the effects of serotonergic psychedelics.
- Modifying serotonergic ligands can reduce psychedelic potential while retaining therapeutic targets.
- Psilocybin and its metabolite psilocin produce region-specific effects on brain activity and gene expression.
Conflicts
- No direct contradictions, but the historical review notes early hypotheses about raphe neurons driving hallucinogenic effects were incorrect, contrasting with later understanding.
Gaps
- Most studies are preclinical or theoretical; clinical efficacy data are lacking.
- Durability of effects and long-term outcomes are not addressed.
- Sample sizes are small, and human studies are absent.
- Dose-response relationships and optimal dosing for therapeutic effects are not fully explored.